- IMGN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $9.6 million.
- IMGN traded 107,539 shares today in the pre-market hours as of 8:44 AM, representing 12.5% of its average daily volume.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in IMGN with the Ticky from Trade-Ideas. See the FREE profile for IMGN NOW at Trade-Ideas More details on IMGN: ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. It develops its products using its antibody-drug conjugates technology. The company offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. Currently there are 4 analysts that rate Immunogen a buy, 2 analysts rate it a sell, and 4 rate it a hold. The average volume for Immunogen has been 1.5 million shares per day over the past 30 days. Immunogen has a market cap of $778.3 million and is part of the health care sector and drugs industry. The stock has a beta of 0.95 and a short float of 18.8% with 14.45 days to cover. Shares are up 47.9% year-to-date as of the close of trading on Thursday. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.